Sunday, January 29, 2023 | Back issues
Courthouse News Service Courthouse News Service

Pharma Merger

A federal class action claims directors are selling ArQule (biopharmaceuticals) too cheaply through an unfair process to Merck Sharp & Dohme, for $20 a share or $2.7 billion.

WILMINGTON, Del. — A federal class action claims directors are selling the biopharmaceutical company ArQule too cheaply through an unfair process to Merck Sharp & Dohme, for $20 a share or $2.7 billion.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...